Design and Characterization of an Anti-Clec9a Antibody Armed with CpG Oligonucleotides To Enable Targeted Delivery of Adjuvant to Cross-Presenting Dendritic Cells
Authors:
- 12 August 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Chemical Biology
Abstract
C-type lectin receptor, Clec9a, is a highly specific receptor expressed on cross-presenting conventional dendritic cells (cDC1). This receptor specificity for this rare population of dendritic cells (DCs), combined with their inherent ability to internalize and localize to the endocytic compartment, presents a unique opportunity for targeted delivery of innate immune agonists. By leveraging an anti-Clec9a antibody, we can specifically deliver these agonists to cross-presenting cDCs, thereby enhancing the cross-priming and expansion of tumor-specific cytotoxic T lymphocytes (CTLs). In this study, we detail the design and characterization of innovative bioconjugates composed of a Clec9a-targeting antibody and CpG oligodeoxynucleotides (ODNs), which activate Toll-like receptor 9 (TLR9) expressed by cDC1. These immunomodulatory bioconjugates exhibited significant cellular activity in cross-presentation assays within a coculture system of in vitro generated CD103+ DCs (iCD103 DCs), tumor cells, and antigen specific CTLs, driving robust cross priming. Furthermore, the targeted delivery of ODNs to cDC1 in vivo demonstrated target-dependent activity in a murine vaccination assay. Our findings underscore the potential of Clec9a-targeted bioconjugates as a powerful strategy to enhance antitumor immunity by precisely delivering adjuvants to cross-presenting dendritic cells.Keywords
This publication has 88 references indexed in Scilit:
- In Vivo and In Vitro Assay to Address Dendritic Cell Antigen Cross-Presenting Capacity2023
- Copper‐Free Click Chemistry: Applications in Drug Delivery, Cell Tracking, and Tissue EngineeringAdvanced Materials, 2021
- CpG Oligonucleotides as Vaccine Adjuvants2020
- Development of the CpG Adjuvant 1018: A Case Study2016
- Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in MelanomaCancer Cell, 2016
- Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotidesAdvanced Drug Delivery Reviews, 2015
- Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell ImmunityCancer Cell, 2014
- Efficient and versatile manipulation of the peripheral CD4+ T‐cell compartment by antigen targeting to DNGR‐1/CLEC9AEuropean Journal of Immunology, 2010
- TLR9 as a key receptor for the recognition of DNA☆Advanced Drug Delivery Reviews, 2008
- Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cellsEuropean Journal of Immunology, 2001